Eunomia perspective · 2025-03-07 · Compliance Programmes, Audits & Training
Managing compliance Risks: Best Practices & Strategies
Published by Eunomia Pharma Services · Updated
How can pharmaceutical companies manage compliance risk?
Key risks include off-label promotion, weak controls, bribery and corruption, conflicts of interest and data privacy breaches. Consequences range from audits and fines to material recalls, public reprimands and suspension from self-regulatory bodies. Management starts with an ethical culture, a robust compliance framework and ongoing monitoring.
Core strategies
- Show visible leadership commitment to ethics.
- Encourage people to raise concerns without fear of retaliation.
- Document policies and procedures aligned to local and international rules.
- Train regularly and monitor for issues.
The practical steps above are Eunomia’s operational guidance. See the source notes below for the scope of the external references.
In the complex and highly regulated landscape of the pharmaceutical industry, managing compliance risks is paramount. Pharmaceutical companies operate under the scrutiny of stringent regulations to ensure ethical conduct and adherence to compliance standards. Effective compliance risk management safeguards a company's reputation and also enables trust in the industry.
Understanding Compliance Risks
The compliance landscape for the pharmaceutical industry is volatile, uncertain, complex, and ambiguous. It encompasses a broad spectrum, including but not limited to:
- Risk of off-label or promotion of unlicensed products
- Lack of controls
- Bribery and Corruption
- Conflict of Interest
- Breach of data privacy clauses
Possible implications of non-compliance
Failure to effectively manage compliance risks can result in significant repercussions for pharmaceutical companies, including:
Regulatory Audits
Authorities may conduct one or many audits to the internal policies and procedures and may also conduct interviews to assess understanding of processs.
Fines and Penalties
Companies and responsible individuals may face financial penalties, criminal sanctions, or prosecutions.
Material Recalls
Non-compliant promotional materials or items may need to be retrieved from HCPs or recalled from distribution
Public Reprimands
Companies may be subject to public reprimands published on self-regulatory code websites (e.g., CGR, ABPI) or reported in medical, pharmaceutical, nursing, and mainstream press.
Suspension or Expulsion
Companies may face suspension or expulsion from self-regulatory bodies countries. This can jeopardise their reputation and have an impact on their ability to operate in those markets.
These consequences highlight the importance of maintaining a proactive and comprehensive compliance framework.
Managing Compliance Risks
Foster an ethical corporate culture
A culture that prioritises ethics and compliance is less likely to encounter compliance violations:
- Leadership Commitment: Leaders should exemplify ethical behaviour and emphasise the importance of compliance.
- Open Communication: Encouraging employees to voice concerns without fear of retaliation promotes transparency.
Establish a robust compliance framework
Developing a comprehensive compliance programme is foundational. This includes:
- Policies and Procedures: Clearly documented guidelines that align with local and international regulations.
- Training and Education: Regular training sessions to ensure employees understand compliance obligations and ethical standards.
- Monitoring and Auditing: Continuous assessment of compliance processes to identify and rectify potential issues.
Leverage technology for compliance
Incorporating advanced technological solutions can enhance compliance efforts such as AI and automation in establishing the right controls and to increase efficiency in processes.
Having a robust risk assessment framework
A well-structured risk assessment framework is essential for identifying, evaluating, and mitigating compliance risks proactively.
Stay abreast of regulatory changes
The regulatory environment is dynamic, necessitating continuous vigilance.
Thus, achieving and maintaining compliance in the pharmaceutical sector can be overwhelming and complex. The ever-changing regulatory environment demands constant vigilance, sharp acumen, and a forward-thinking approach. Eunomia's team of dedicated healthcare compliance experts, armed with industry-specific knowledge and experience, is well-equipped to address the unique challenges faced by pharmaceutical companies today.
Eunomia can ensure that the requirements of various laws and self-regulatory requirements across Europe are met, including but not limited to ABAC, IFPMA, EFPIA, and various country-specific requirements. We eagerly look forward to collaborating with pharmaceutical businesses to build a stronger, more compliant industry.
Sources and scope
- Ministry of Justice: Bribery Act 2010 guidance
UK guidance on adequate procedures to prevent bribery; it is not a healthcare-specific checklist.
- UK Bribery Act 2010, section 7
The corporate offence of failing to prevent bribery by associated persons.
External sources accessed 29 September 2026. Check the applicable country rules and current source text for a specific engagement.